Changes in the Genomic Spectrum of Actionable Alterations in HER2 Negative Metastatic Breast Cancer in Serial Cell Free DNA (cfDNA) Analysis

被引：0
|
作者：
Bar, Yael
Keenan, Jennifer C.
Ryan, Lianne
Juric, Dejan
Shin, Jennifer
Wander, Seth A.
Spring, Laura M.
Moy, Beverly
Ellisen, Leif
Isakoff, Steven J.
Bardia, Aditya
Vidula, Neelima
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P4-01-14
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-01-14
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer
    Bar, Yael
    Keenan, Jennifer C.
    Niemierko, Andrzej
    Medford, Arielle J.
    Isakoff, Steven J.
    Ellisen, Leif W.
    Bardia, Aditya
    Vidula, Neelima
    NPJ BREAST CANCER, 2024, 10 (01)
  • [2] Cell free DNA analysis identifies actionable ERBB2 amplifications in patients with HER2 negative breast cancer
    Raymond, Victoria M.
    Diaz, Joseph
    Banks, Kimberly C.
    Ahn, Eugene
    Brufsky, Adam
    Ellis, Matthew
    Lippman, Marc
    Lee, Christine
    Pluard, Timothy
    Schreeder, Marshall
    Schwab, Richard
    Lanman, Richard B.
    CANCER RESEARCH, 2018, 78 (04)
  • [3] Serial genomic analysis of circulating free DNA and change of immune-related gene signature in triple negative and HER2 positive advanced, metastatic breast cancer
    Lee, Jieun
    Shin, Kabsoo
    Joe, Seung Yeon
    Lee, Hayoon
    Jeon, Byung Hee
    Lee, Ahwon
    CANCER RESEARCH, 2023, 83 (05)
  • [4] Cell free DNA analysis identifies actionable ERBB2 am plifications in patients with HER2 equivocal breast cancer
    Rich, T. A.
    Raymond, V. M.
    Ahn, E. R.
    Banks, K. C.
    Brufsky, A.
    Lee, C.
    Lippman, M.
    Pluard, T. J.
    Schwab, R. B.
    Lanman, R. B.
    CANCER RESEARCH, 2019, 79 (04)
  • [5] Precision medicine for HER2 negative metastatic breast cancer
    Hara, Fumikata
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer
    Kyoungmin Lee
    Jongwon Lee
    Jungmin Choi
    Sung Hoon Sim
    Jeong Eun Kim
    Min Hwan Kim
    Yeon Hee Park
    Jee Hyun Kim
    Su-Jin Koh
    Kyong Hwa Park
    Myoung Joo Kang
    Mi Sun Ahn
    Kyoung Eun Lee
    Hee-Jun Kim
    Hee Kyung Ahn
    Han Jo Kim
    Keon Uk Park
    In Hae Park
    Scientific Reports, 13
  • [7] Identification of pathogenic RET alterations in cell-free DNA (cfDNA) from patients with metastatic breast cancer
    Taylor, Mary Love
    Mayro, Benjamin
    Drusbosky, Leylah
    Anders, Carey
    Force, Jeremy
    CANCER RESEARCH, 2021, 81 (04)
  • [8] The Genomic Landscape of ER Positive, HER2 Negative Breast Cancer
    Ramakrishna, M.
    Martin, S.
    Campbell, P. J.
    Futreal, P. A.
    Stratton, M. R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S132 - S132
  • [9] Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines
    Arriola, Edurne
    Marchio, Caterina
    Tan, David Sp
    Drury, Suzanne C.
    Lambros, Maryou B.
    Natrajan, Rachael
    Rodriguez-Pinilla, Socorro Maria
    Mackay, Alan
    Tamber, Narinder
    Fenwick, Kerry
    Jones, Chris
    Dowsett, Mitch
    Ashworth, Alan
    Reis-Filho, Jorge S.
    LABORATORY INVESTIGATION, 2008, 88 (05) : 491 - 503
  • [10] Activating HER2 missense mutations in HER2-negative metastatic breast cancer
    Shah, Mirat
    Ensminger, Jennifer
    Wang, Chenguang
    Ali, Siraj
    Chung, Jon
    Lauring, Josh
    Park, Ben Ho
    Stearns, Vered
    CANCER RESEARCH, 2020, 80 (04)
12345